

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Approval for Drug Registration of Licensed-in Pharmaceutical Product” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Yuqing

Chairman

Shanghai, the PRC

27 August 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* for identification purposes only

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Approval for Drug Registration of Licensed-in Pharmaceutical Product

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement, or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

On 28 May 2026, Yao Pharmaceutical Company Limited.* (重慶藥友製藥有限責任公司) (the “**Yao Pharma**”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the “**Company**”), entered into a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd.* (重慶智翔金泰生物製藥股份有限公司) (the “**Genrix Bio**”), pursuant to which Yao Pharma was granted the sole and exclusive rights to the clinical development and commercialization of the licensed product (namely a bispecific antibody product that uses GR1803 as the sole active ingredient and/or as agreed, simultaneously targeting BCMA and CD3) within the licensed territory (i.e., the Chinese mainland¹, Hong Kong, Macau and Taiwan regions) and the licensed field (i.e., for the diagnosis, prevention and treatment of human diseases), as well as the exclusive rights to the research and production of manufacturing processes, and Yao Pharma will act as the marketing authorization holder (MAH) of the product in the licensed territory. For details, please refer to the relevant announcements published by the Company on 29 May 2026 in the China Securities Journal, Shanghai Securities News, Securities Times and on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>).

¹ Excluding Hong Kong, Macau and Taiwan regions (the same applies below).

Recently, the marketing registration application for GR1803 Injection (Generic name: Velinotamig Injection, trade name in the Chinese mainland: 维可妥[®]; the “**Drug**”) has been approved with conditions by the National Medical Products Administration, for the indication of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy (including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody) .

II. Registration Information of the Drug

Generic Name: Velinotamig Injection

Dosage Form: Injection

Strength: 20 mg (2 ml)/vial

Registered Category: Therapeutic Biological Product Category 1

Manufacturer: Chongqing Genrix Biopharmaceutical Co.,Ltd. * (重慶智翔金泰生物製藥股份有限公司)

Drug Approval Number: Guo Yao Zhun Zi S20260066

III. Research and Development of the Drug and Marketing Situation of Similar Drugs

GR1803 is a bispecific antibody that can simultaneously bind to BCMA and CD3 antigens, thereby redirecting cytotoxic T cells to cells expressing BCMA. Apart from the approved indication for registration, as at the date of this announcement (i.e., 27 August 2026, the same hereinafter), multiple clinical studies of the Drug for the treatment of adult relapsed or refractory multiple myeloma and systemic lupus erythematosus are orderly advancing in Chinese mainland.

According to the latest data² of IQVIA MIDAS™, the global sales of BCMA×CD3 targeted antibody products in 2025 was approximately USD1,139 million. As at the date of this announcement, two BCMA×CD3 targeted antibody products have been conditionally approved for marketing in the PRC, namely Elranatamab Injection of Pfizer Inc. (approved for marketing in March 2025) and Teclistamab Injection of Janssen-Cilag International NV (approved for marketing in June 2024).

² Provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world.

IV. Impact on the Listed Company and Risk Warning

The approval for marketing of the Drug will provide a new treatment option for adult patients with relapsed or refractory multiple myeloma in the Chinese mainland and will further enrich the product line of the Group (i.e., the Company and its subsidiaries/units). Subsequently, Yao Pharma and Genrix Bio will advance the procedures for the change of the marketing authorization holder (MAH) of the Drug in accordance with the agreement.

Due to the industry characteristics of pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

27 August 2026

** For identification purposes only*